Abstract
Rare diseases, while individually rare, collectively affect approximately 10% of the global population. In China, an estimated 16.8 million people live with these conditions, facing significant challenges in diagnosis and treatment. While patient organizations (POs) in Western countries play a critical role in advocacy and research, their counterparts in China remain in an early, fragile stage of development. This study interviews leaders from 28 Chinese POs to assess their unmet needs. Findings reveal a lack of official registration, limited financial resources, and minimal government support. Most organizations prioritize basic survival and peer support over research sponsorship. To improve outcomes, the study recommends specialized insurance programs, increased research stimulation, and the implementation of an "Orphan Drug Act" in China.
Introduction: The Rare Disease Crisis in China
Individually, a rare disease affects a small subset of the population and is often neglected by mainstream healthcare systems. However, with over 7,000 known rare diseases, the cumulative impact is massive. In China, the rare disease ecosystem is significantly underdeveloped compared to Western nations. Patients often endure a "diagnostic odyssey" marked by frequent misdiagnosis and a dearth of accessible therapies.
Patient organizations (POs) are vital for bridging the gap between clinical neglect and active therapy development. They raise awareness, provide peer support, and, in many regions, fund critical research. This paper maps the current status of Chinese POs, identifies their most pressing unmet needs, and provides a roadmap for policymakers to empower these community pillars.
Methodology
The researchers conducted a qualitative, interview-based study involving leaders from 28 distinct rare disease POs. Participants were recruited through online advertisements and webinars.
- Data Collection: One-on-one semi-structured interviews (1–2 hours) were conducted via phone between March and May 2020.
- Analysis: Interviews were transcribed verbatim and analyzed to categorize organizational structures, financial health, and specific operational challenges.
- Scope: Unlike previous disease-specific studies, this research provides a broad cross-disease perspective on the organizational health of Chinese POs.
The Organizational Landscape
The study highlights a fragile ecosystem where most organizations operate on the fringes of formal recognition. A significant majority of these groups originated as online chat communities (e.g., QQ or WeChat). While effective for rapid community building, these platforms are less suited for the long-term storage and categorization of medical information than traditional web infrastructures.
Key organizational findings include:
- Institutional Invisibility: Only 5 of the 28 organizations were officially registered with the government. This lack of legal status prevents them from opening bank accounts, hiring full-time staff, or applying for large-scale grants.
- The "Founder's Burden": Nearly 90% of PO leaders are patients or family members. Many fund organizational activities personally, leading to high burnout and financial instability.
- Research Gap: Unlike their Western counterparts, Chinese POs are almost entirely excluded from the research phase due to a lack of funding, focusing instead on basic peer support.
Key Results and Policy Recommendations
The interviews identified several systemic hurdles and clear pathways for improvement:
- Primary Challenges: 71.4% of leaders cited a lack of public awareness as their primary hurdle, followed by a lack of financial resources (67.9%).
- Support Deficit: Only 3.6% of organizations received support from the central government, while 75% relied on other non-profits for assistance.
- Insurance and Legislation: 82.1% of interviewees called for specialized insurance programs, as rare disease treatments are frequently excluded from national medical insurance. Furthermore, 71.4% recommended an "Orphan Drug Act" to provide market exclusivity and tax incentives for drug development.
Conclusion
Patient organizations in China are currently fighting for basic survival. To transition from informal support groups to powerful engines for research and legislation, they require systemic support. The study concludes that empowering these organizations through legal recognition, financial aid, and targeted policy changes—such as an Orphan Drug Act—is essential for improving the lives of millions of rare disease patients in China.
Future work should involve larger-scale quantitative surveys to validate these findings across a broader range of diseases and track the impact of recent policy shifts, such as the 2018 "First National List of Rare Diseases."
Summary updated